@tiff_bey's Zepbound claims need more context

What did @tiff_bey actually say?

The creator gave her followers a walkthrough of Eli Lilly's self-pay program for Zepbound, the FDA-approved tirzepatide injection. She said the 2.5 mg vial runs "$349 a month" and that "all the other vials are $499 a month." She also mentioned that insured patients can get it for "$25 a month," and described the logistics: doctor submits a prescription, Lilly texts you a payment link, and delivery usually arrives next day. That is the core of the video.

This is practical, patient-to-patient information about a real manufacturer program, not a medical claim. That framing matters when we evaluate what she got right and what has changed since she filmed this.

Does the science back this up?

There is no clinical trial to cite here because this is a pricing and logistics video, not a health claims video. But the underlying drug is well-studied. Tirzepatide's approval for weight management (Zepbound) was supported by the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), which showed up to 22.5% mean body weight reduction over 72 weeks in adults with obesity. That trial used injections in the same dose range the creator references.

What does have an evidence gap is whether Lilly's self-pay vial program delivers equivalent clinical outcomes to the autoinjector pen version studied in trials. The vials are the same drug and the same doses, but the vial format was introduced partly in response to supply shortages, and the filling and administration steps differ. That is not a reason to avoid them, but it is worth knowing.

What did they get wrong (or right)?

The pricing she cites was accurate when Eli Lilly launched the self-pay vial program in late 2023 and through much of 2024. The $349 starting dose and $499 for higher doses matched Lilly's published Zepbound for Cash pricing at that time. Give her credit for that.

The $25 copay claim is more complicated. Lilly's savings card has offered $25 per month for commercially insured patients, but that offer has eligibility restrictions. It does not apply to patients using government insurance like Medicare or Medicaid. It also requires enrollment in Lilly's savings program and is subject to change. Saying it is simply "$25 a month" if you have insurance is incomplete and could mislead someone who has Medicare coverage and assumes they qualify.

The "next day delivery" claim is plausible based on user reports but is not guaranteed and varies by pharmacy or delivery partner. Treating it as a reliable expectation could set patients up for frustration.

What should you actually know?

Lilly's self-pay program is real and it has made tirzepatide meaningfully more accessible. But a few things this video does not cover matter a lot.

• Prices can change. Lilly has adjusted the self-pay vial pricing before, so always verify on their official site before budgeting.
• The $25 copay savings card is only for commercially insured patients. Medicare and Medicaid beneficiaries are excluded by federal law from manufacturer coupons.
• You still need a valid prescription from a licensed provider. The video mentions this, but it is worth repeating because some patients try to use telehealth platforms to work around this requirement.
• Vials require proper reconstitution and storage. Unlike the autoinjector pen, the vial format involves more steps and room for user error.
• Compounded tirzepatide is a separate product entirely. It is not the same as Lilly's brand-name Zepbound, and the FDA has flagged safety concerns about compounded versions.

If you are paying out of pocket, check whether your state has a telehealth provider who can prescribe through the Lilly direct program. It is a legitimate option, but go in with current pricing, not what someone posted on TikTok.